Literature DB >> 20049448

Health-related quality of life and its associations with mood condition in familial Mediterranean fever patients.

Serpil Muge Deger1, Mehmet Akif Ozturk, Mehmet D Demirag, Selcuk Aslan, Berna Goker, Seminur Haznedaroglu, A Mesut Onat.   

Abstract

The aim of the present study was to investigate the health-related quality of life (HRQOL) and mood conditions in familial Mediterranean fever (FMF) patients. Ninety FMF patients (F/M 60/30, median age 29) and 67 control subjects (F/M 46/21, median age 30) were included in this study. HRQOL was assessed with short form-36 (SF-36) and mood conditions were assessed with hospital anxiety depression scale (HADS). FMF patients had significantly lower mean scores on SF-36 physical components compared to the control group. However, mental components were comparable between groups. FMF patients were significantly more likely to have depression and anxiety compared to the control group [30 (33%) vs. 8 (12%), respectively, χ (2) = 9.58, OR (95% CI) = 3.7 (1.5-8.7), p < 0.01 for depression and 48 (53%) and 11 (16%), respectively, χ (2) = 22.31, OR (95% CI) = 5.8 (2.7-12.5), p < 0.001 for anxiety]. When frequency of anxious subjects was adjusted for the presence of concomitant depressive status as a confounding factor, the difference between the groups remained statistically significant [χ (2) = 11.86, OR (95% CI) = 5.4 (2.1-13.7), p < 0.01]. However, the difference of depression status between groups was not statistically significant when adjusted for the presence of concomitant anxiety status [χ (2) = 0.08, OR (95% CI) = 1.3 (0.5-3.8), p = 0.78] and FMF was found to be independently associated with only anxiety [OR (95% CI) = 7.1 (2.3-20.3)]. In addition, pure anxious FMF subgroup had significantly lower scores of mental health and mental component summary when compared to normal mood subgroup. In conclusion, FMF might adversely affect HRQOL. Depression and anxiety are more frequent in FMF patients than healthy subjects.

Entities:  

Mesh:

Year:  2010        PMID: 20049448     DOI: 10.1007/s00296-009-1334-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  39 in total

1.  Inflammatory markers in late-life depression: results from a population-based study.

Authors:  M A Bremmer; A T F Beekman; D J H Deeg; B W J H Penninx; M G Dik; C E Hack; W J G Hoogendijk
Journal:  J Affect Disord       Date:  2007-08-22       Impact factor: 4.839

2.  Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project.

Authors:  Jordi Alonso; Montserrat Ferrer; Barbara Gandek; John E Ware; Neil K Aaronson; Paola Mosconi; Niels K Rasmussen; Monika Bullinger; Shunichi Fukuhara; Stein Kaasa; Alain Leplège
Journal:  Qual Life Res       Date:  2004-03       Impact factor: 4.147

3.  Comorbid anxiety disorder and the functioning and well-being of chronically ill patients of general medical providers.

Authors:  C D Sherbourne; K B Wells; L S Meredith; C A Jackson; P Camp
Journal:  Arch Gen Psychiatry       Date:  1996-10

4.  Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study.

Authors:  Brenda W J H Penninx; Stephen B Kritchevsky; Kristine Yaffe; Anne B Newman; Eleanor M Simonsick; Susan Rubin; Luigi Ferrucci; Tamara Harris; Marco Pahor
Journal:  Biol Psychiatry       Date:  2003-09-01       Impact factor: 13.382

5.  Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy.

Authors:  E Keystone; G R Burmester; R Furie; J E Loveless; P Emery; J Kremer; P P Tak; M S Broder; E Yu; M Cravets; F Magrini; F Jost
Journal:  Arthritis Rheum       Date:  2008-06-15

6.  Quality of life over time in patients with systemic lupus erythematosus.

Authors:  Bindee Kuriya; Dafna D Gladman; Dominque Ibañez; Murray B Urowitz
Journal:  Arthritis Rheum       Date:  2008-02-15

7.  Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder.

Authors:  Cengiz Tuglu; S Hakan Kara; Okan Caliyurt; Erdal Vardar; Ercan Abay
Journal:  Psychopharmacology (Berl)       Date:  2003-08-30       Impact factor: 4.530

Review 8.  Medical co-morbidity in depressive disorders.

Authors:  Tami Benton; Jeffrey Staab; Dwight L Evans
Journal:  Ann Clin Psychiatry       Date:  2007 Oct-Dec       Impact factor: 1.567

9.  Serum proinflammatory cytokines directing T helper 1 polarization in patients with familial Mediterranean fever.

Authors:  Ismail Simsek; Salih Pay; Aysel Pekel; Ayhan Dinc; Ugur Musabak; Hakan Erdem; Ali Sengul
Journal:  Rheumatol Int       Date:  2007-01-17       Impact factor: 3.580

10.  Interleukin-18 and CD30 serum levels in patients with moderate-severe depression.

Authors:  Rosaria Alba Merendino; Antonio Enrico Di Rosa; Giuseppe Di Pasquale; Paola Lucia Minciullo; Carmela Mangraviti; Antonella Costantino; Antonella Ruello; Sebastiano Gangemi
Journal:  Mediators Inflamm       Date:  2002-08       Impact factor: 4.711

View more
  12 in total

1.  The evaluation of anxiety, depression and quality of life scores of children and adolescents with familial Mediterranean fever.

Authors:  Arzu Önal Sönmez; Hafize Emine Sönmez; Mustafa Çakan; Mesut Yavuz; Gonca Keskindemirci; Nuray Aktay Ayaz
Journal:  Rheumatol Int       Date:  2020-01-25       Impact factor: 2.631

2.  Effect of interleukin-1 antagonists on the quality of life in familial Mediterranean fever patients.

Authors:  Ozkan Varan; Hamit Kucuk; Hakan Babaoglu; Nuh Atas; Reyhan Bilici Salman; Hasan Satis; Mehmet Akif Ozturk; Seminur Haznedaroglu; Berna Goker; Abdurrahman Tufan
Journal:  Clin Rheumatol       Date:  2018-12-10       Impact factor: 2.980

3.  Fatigue in familial Mediterranean fever and its relations with other clinical parameters.

Authors:  Mehmet Tuncay Duruoz; Cagri Unal; Duygu Karali Bingul; Firat Ulutatar
Journal:  Rheumatol Int       Date:  2017-11-14       Impact factor: 2.631

Review 4.  Chronic inflammation in FMF: markers, risk factors, outcomes and therapy.

Authors:  Ilan Ben-Zvi; Avi Livneh
Journal:  Nat Rev Rheumatol       Date:  2010-11-09       Impact factor: 20.543

Review 5.  [Evidence-based treatment recommendations for familial Mediterranean fever : A joint statement by the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatology].

Authors:  T Kallinich; N Blank; T Braun; E Feist; U Kiltz; U Neudorf; P T Oommen; C Weseloh; H Wittkowski; J Braun
Journal:  Z Rheumatol       Date:  2019-02       Impact factor: 1.372

6.  Canakinumab as rescue therapy in familial Mediterranean fever refractory to conventional treatment.

Authors:  Mirella Alpa; Dario Roccatello
Journal:  Drug Des Devel Ther       Date:  2015-04-17       Impact factor: 4.162

7.  The effect of rilonacept versus placebo on health-related quality of life in patients with poorly controlled familial Mediterranean fever.

Authors:  Philip J Hashkes; Steven J Spalding; Rula Hajj-Ali; Edward H Giannini; Anne Johnson; Karyl S Barron; Michael H Weisman; Noune Pashinian; Andreas O Reiff; Jonathan Samuels; Dowain Wright; Daniel J Lovell; Bin Huang
Journal:  Biomed Res Int       Date:  2014-05-15       Impact factor: 3.411

8.  Health-related quality of life in children with PFAPA syndrome.

Authors:  Claire Grimwood; Isabelle Kone-Paut; Maryam Piram; Linda Rossi-Semerano; Véronique Hentgen
Journal:  Orphanet J Rare Dis       Date:  2018-08-09       Impact factor: 4.123

9.  Familial Mediterranean fever: Health-related quality of life and associated variables in a national cohort.

Authors:  Hatice Bodur; Fatma Gül Yurdakul; Mehmet Tuncay Duruöz; Hasan Fatih Çay; Ülkü Uçar; Yaşar Keskin; Betül Sargin; Gülcan Gürer; Ozan Volkan Yurdakul; Mustafa Çaliş; Hülya Deveci; Yıldıray Aydin; Sami Hizmetli; Remzi Çevik; Ali Yavuz Karahan; Şebnem Ataman; Hilal Ecesoy; Zafer Günendi; Murat Toprak; Nesrin Şen; Duygu Altintaş; Ahmet Kıvanç Cengiz; Gökhan Çağlayan; Ali Nail Demir; Hüseyin Kaplan; Sertaç Ketenci; Meltem Alkan Melikoğlu; Mehmet Nayimoğlu; Kemal Nas; Banu Sarifakioğlu; İlhan Sezer
Journal:  Arch Rheumatol       Date:  2020-12-10       Impact factor: 1.472

10.  [Results of the systematic literature search as basis for the "Evidence-based treatment recommendations for familial Mediterranean fever patients with insufficient response or intolerability to colchicine" of the Society for Pediatric and Adolescent Rheumatology and the German Society for Rheumatology].

Authors:  T Sahr; U Kiltz; C Weseloh; T Kallinich; J Braun
Journal:  Z Rheumatol       Date:  2020-09-30       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.